Contrary to current opinion, genomic instability is not the origin of cancer in patients with short telomere syndromes (STSs), researchers from the Johns Hopkins University School of Medicine reported April 2, 2023, in Cancer Cell. Instead, short telomeres appeared to cause memory T-cell dysfunction that increased the risk of a small number of tumor types in individuals with STS. Such syndromes can cause premature aging of different physiological systems.
CSPC Pharmaceutical Group Ltd. has received FDA clearance of its IND for a phase I trial of its antibody-drug conjugate CPO-301 for the treatment of advanced lung cancer with alterations in the EGFR gene or EGFR over-expression.
Immunoprecise Antibodies Ltd.'s Talem Therapeutics LLC subsidiary has entered into a research collaboration and exclusive option license agreement with Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc.
Chimeric antigen receptor (CAR) T-cell therapy is a powerful approach for patients with hematologic malignancies, such as leukemia. Its broad use may be associated with life-threatening toxicities such as neurotoxicity and cytokine release syndrome (CRS).
Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy.
Ono Pharmaceutical Co. Ltd. has entered into a worldwide drug discovery collaboration agreement with Macomics Ltd. to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.
Shuttle Pharmaceuticals Holdings Inc. has entered a research agreement with Georgetown University focused on the evaluation of the company's lead histone deacetylase 6 (HDAC6) inhibitor candidate, SP-2-225, evaluating the antitumor effect of the combination of SP-2-225 and radiation therapy in a syngeneic breast cancer model.
RSS
